Építés alatt – nem éles oldal
Belépés
Befejeződött2. fázis

Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study

A legfontosabb adatok

Ki végzi
MAPS Europe B.V.
Hol
Csehország, Egyesült Királyság, Hollandia, Németország és Norvégia6 helyszín, 5 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Fázis
2. fázis
Résztvevők
21 fő vett részt
Kezdés
2020. jún. 24.
Befejezés
2023. dec. 15.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Midomafetamine HCl
A regiszteradat frissítve
2025. január 28.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 17 feltétel megnézéseKevesebb

Ki vehet részt

  • Are at least 18 years old
  • Are fluent in speaking and reading the predominantly used or recognized language of the study site
  • Are able to swallow pills
  • Agree to have study visits video-recorded, including Experimental Sessions, Independent Rater assessments, and non-drug psychotherapy sessions
  • Must provide a contact (relative, spouse, close friend or other support person) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal or unreachable
  • Must agree to inform the investigators within 48 hours of any medical treatments and procedures
  • People able to become pregnant (PABP) (i.e., assigned female at birth, fertile, following menarche and until becoming post-menopausal unless permanently sterile), must have a highly sensitive negative pregnancy test at study entry and prior to each Experimental Session, and must agree to use adequate birth control through 10 days after the last Experimental Session. Adequate birth control methods include intrauterine device (IUD), injected or implanted hormonal methods, abstinence, oral hormones plus a barrier contraception, vasectomized sole partner
  • Agree to the following lifestyle modifications: comply with requirements for fasting and refraining from certain medications prior to Experimental Sessions, not enroll in any other interventional clinical trials during the duration of the study, remain overnight at the study site after each Experimental Session and be driven home after, and commit to medication dosing, therapy, and study procedures

Ki nem vehet részt

  • Require ongoing concomitant therapy with a psychiatric medication (exceptions apply)
  • Have a history of any medical condition that could make receiving a sympathomimetic drug harmful because of increases in blood pressure (BP) and heart rate
  • Have used Ecstasy (material represented as containing MDMA) more than 10 times within the last 10 years or at least once within 6 months of the first Experimental Session; or have previously participated in a clinical trial conducted by the sponsor
  • Have current alcohol or substance use disorder
  • Are not able to give adequate informed consent
  • Have any current problem which, in the opinion of the investigator or Medical Monitor, might interfere with participation
  • Would present a serious risk to others as established through clinical interview and contact with treating psychiatrist
  • Weigh less than 48 kilograms (kg)
  • Are pregnant or nursing or are able to become pregnant and are not practicing an effective means of birth control

Hol van ez a vizsgálat?

5 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people diagnosed with at least severe PTSD.

A teljes eredeti leírásKevesebb

The main question it aims to answer is: Do two open-label sessions of MDMA-assisted therapy reduce PTSD symptoms?

Participants will receive three non-drug preparatory sessions followed by two sessions of MDMA-assisted therapy. Each MDMA-assisted therapy session is followed by three non-drug integrative therapy sessions.

A vizsgálat csoportja

  • Experimental: MDMA-assisted psychotherapyA vizsgált kezelés

    Administration of 80 to 120 mg midomafetamine (MDMA) HCl followed by a supplemental half-dose 1.5 to 2 hrs after the initial dose of 40 or 60 mg, respectively, in combination with manualized psychotherapy.

    Kezelés: Midomafetamine HCl

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
An Open-Label, Phase 2, Multicenter Feasibility Study of Manualized MDMA-Assisted Psychotherapy With an Optional fMRI Sub-Study Assessing Changes in Brain Activity in Subjects With Posttraumatic Stress Disorder
A regiszteradat frissítve
2025. január 28.